Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion
Swiss drugmaker Novartis agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion.
(USA Today, 2025-10-26T19:43:33Z)